Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
제품번호 | 종 | 제품 설명 | 구조 | 순도 | 특징 |
---|---|---|---|---|---|
TTR-H5223 | Human | Human Transthyretin / Prealbumin Protein, His Tag |
|
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tafamidis Meglumine | FX-1006A; PF-6291826; Fx-1006A; PF-06291826 | Approved | Pfizer Inc | Vyndaqel, 维达全 | Mainland China | Amyloid Neuropathies | Pfizer Europe Ma Eeig | 2011-11-16 | Amyloid Neuropathies, Familial; Heart Diseases; Immunoglobulin Light-chain Amyloidosis; Cardiomyopathies; Amyloidosis; Amyloid Neuropathies; Transthyretin amyloidosis | Details |
Vutrisiran | ALN-TTRSC02 | Approved | Alnylam Pharmaceuticals Inc | AMVUTTRA | Japan | Transthyretin amyloidosis | Alnylam Japan Kk | 2022-06-13 | Amyloid Neuropathies, Familial; Amyloidosis, Familial; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis | Details |
Tafamidis | PF-6291826; Fx-1006A; PF-06291826; FX-1006A | Approved | Pfizer Inc | 维万心, VYNDAMAX | Mainland China | Transthyretin amyloidosis | Pfizer Europe Ma Eeig | 2019-05-03 | Heart Diseases; Transthyretin amyloidosis | Details |
Patisiran | SAR-438037; GENZ-438027; ALN-TTR02; ALN-18328 | Approved | Alnylam Pharmaceuticals Inc | Onpattro | Japan | Transthyretin amyloidosis | Alnylam Pharmaceuticals Inc | 2018-08-10 | Amyloidosis, Familial; Amyloid Neuropathies, Familial; Polyneuropathies; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies | Details |
Inotersen sodium | ISIS-420915; GSK-2998728 | Approved | Ionis Pharmaceuticals Inc | Tegsedi | United States | Transthyretin amyloidosis | Akcea Therapeutics Inc, Ptc Therapeutics Inc | 2018-07-05 | Adenomatous Polyposis Coli; Amyloid Neuropathies, Familial; Amyloidosis; Transthyretin amyloidosis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NTLA-2001 | NTLA-2001 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc, Intellia Therapeutics Inc | Amyloidosis, Familial; Cardiomyopathies; Transthyretin amyloidosis; Amyloid Neuropathies | Details |
NNC6019-0001 | NNC6019-0001; NNC-6019; PRX-004 | Phase 2 Clinical | Novo Nordisk A/S | Immunoglobulin Light-chain Amyloidosis; Cardiomyopathies | Details |
Eplontersen | ION-682884; ION-TTR-LRx; IONIS-TTR-LRx; AKCEA-TTR-LRx | Phase 3 Clinical | Ionis Pharmaceuticals Inc | Amyloid Neuropathies, Familial; Cardiomyopathies; Transthyretin amyloidosis | Details |
NI-006 | NI-006 | Phase 1 Clinical | Neurimmune Ag | Cardiomyopathies; Transthyretin amyloidosis | Details |
Acoramidis | AG-10; ALXN-2060; BBP-265 | Phase 3 Clinical | Stanford University, Bridgebio Pharma Inc | Amyloidosis, Familial; Heart Diseases; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies | Details |
This web search service is supported by Google Inc.